Biohaven Pharmaceutical
Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Launch date
Employees
Market cap
$3.6b
Enterprise valuation
$3.2b (Public information from Sep 2024)
Share price
$39.4 BHVN
New Haven Connecticut (HQ)
Authorizing premium user...